AbbVie Inc. (ABBV): New Analyst Report from Zacks Equity Research - Zacks ... NASDAQ ... (phase III ongoing for triple negative breast cancer), elotuzumab (multiple myeloma phase III studies ongoing with results due in early 2015 partnered with Bristol-Myers Squibb) and daclizumab (relapsing remitting multiple sclerosis partnered with ... |
